- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07625462
Hearing and Brain Development Cohort in Children and Adolescents (HBD-Cohort)
3. juni 2026 oppdatert av: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Longitudinal Cohort Study of Hearing and Brain Development in Children and Adolescents With Hearing Loss Across Different Hearing Management Pathways and in Normal-Hearing Controls
This bidirectional observational cohort study aims to establish a Hearing and Brain Development (HBD) cohort in children and adolescents with hearing loss across different hearing management pathways, including hearing aid fitting, cochlear implantation, auditory brainstem implantation, gene therapy, and follow-up without intervention, as well as in a normal-hearing control group.
Participants will undergo longitudinal assessments of hearing, speech, language, neurodevelopment, and multimodal brain function.
Studieoversikt
Status
Rekruttering
Forhold
Studietype
Observasjonsmessig
Registrering (Antatt)
5000
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Yun Li
- Telefonnummer: +86-21-53314064
- E-post: liyuncmm@126.com
Studiesteder
-
-
-
Shanghai, Kina, 200011
- Rekruttering
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
-
Ta kontakt med:
- Yun Li
- Telefonnummer: +86-21-53314064
- E-post: liyuncmm@126.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Ja
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
The study population consists of children and adolescents aged 0 to 18 years who are evaluated and/or managed at the Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.
The cohort includes participants with hearing loss across different hearing management pathways, including hearing aid fitting, cochlear implantation, auditory brainstem implantation, gene therapy, and follow-up without intervention, as well as a normal-hearing control group.
Beskrivelse
Inclusion Criteria:
- Age no more than 18 years.
- For the HA/CI/ABI/GT/FU groups: behavioral or pure-tone hearing threshold >=20 dB HL, or air-conduction ABR >=35 dB nHL; For the normal-hearing control group: participants diagnosed as normal hearing by experienced physicians.
Exclusion Criteria:
- Inability to cooperate with study testing procedures.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
HA
Participants suitable for unilateral or bilateral hearing aid(s) fitting, without any other intervention methods (cochlear implantation, gene therapy treatment, auditory brainstem implantation, etc.).
|
|
CI
Participants suitable for unilateral or bilateral cochlear implantation, without gene therapy treatment or auditory brainstem implantation.
|
|
ABI
Participants suitable for unilateral or bilateral auditory brainstem implantation.
|
|
GT
Participants suitable for gene therapy treatment.
|
|
FU
Participants with hearing loss who do not receive any intervention.
|
|
NH Control
Participants with normal hearing who are enrolled as healthy controls.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Categories of Auditory Performance-II Score
Tidsramme: From baseline to 24-month follow-up
|
The Categories of Auditory Performance-II scale will be used to assess auditory performance.
Scores range from 0 to 9, with higher scores indicating better auditory performance.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Speech Intelligibility Rating Score
Tidsramme: From baseline to 24-month follow-up
|
The Speech Intelligibility Rating scale will be used to assess speech intelligibility.
Scores range from 1 to 5, with higher scores indicating better speech intelligibility.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in MRI-derived Brain Development Deviation Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The MRI-derived Brain Development Deviation Composite Score will be calculated from pre-specified multimodal brain magnetic resonance imaging measures using age-adjusted normative models.
All pre-specified MRI measures will be combined into a single standardized composite score before analysis.
The score summarizes the magnitude of deviation from age-expected brain development.
Higher values indicate greater deviation from age-expected brain development.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Parent-Child Interaction Quality Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The Parent-Child Interaction Quality Composite Score will be used to assess parent-child interaction quality based on a pre-specified observational coding scheme.
The composite score summarizes overall interaction quality during recorded parent-child interaction tasks.
Higher scores indicate better parent-child interaction quality.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Griffiths Mental Development Scales General Development Score
Tidsramme: From baseline to 24-month follow-up
|
The Griffiths Mental Development Scales will be used to assess general developmental level.
The general development score reflects overall developmental functioning across multiple developmental domains.
Higher scores indicate better general developmental functioning.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Ages and Stages Questionnaires: Social-Emotional, Second Edition Total Score
Tidsramme: From baseline to 24-month follow-up
|
The Ages and Stages Questionnaires: Social-Emotional, Second Edition will be used to assess social-emotional development.
Total scores vary by age-specific form, with higher scores indicating greater social-emotional concern.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Adaptive Behavior Assessment System, Second Edition General Adaptive Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The Adaptive Behavior Assessment System, Second Edition will be used to assess adaptive behavior.
The General Adaptive Composite score summarizes overall adaptive functioning across daily living, communication, social, and practical adaptive skill areas.
Higher scores indicate better adaptive functioning.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Hao Wu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
- Studiestol: Hao Wu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
20. mai 2026
Primær fullføring (Antatt)
31. desember 2030
Studiet fullført (Antatt)
31. desember 2030
Datoer for studieregistrering
Først innsendt
20. mai 2026
Først innsendt som oppfylte QC-kriteriene
3. juni 2026
Først lagt ut (Faktiske)
4. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. juni 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HBD-Cohort
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-delingstidsramme
The IPD will be available beginning 6 months after study completion.
Tilgangskriterier for IPD-deling
Detailed data are available upon reasonable request.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .